Tier 4 — mechanistic

Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics

Gu Y, Zhang Y, Shi X, Li X, Hong J, Chen J, Gu W, Lu X, Xu G, Ning G
Talanta 2010 81(3):766-772

Bibliography

PubMed
PMID 20298851
DOI
10.1016/j.talanta.2010.01.015
Funding
Funding was not established from the accessible source; this is not a declaration of no funding.
Competing interests
A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Study snapshot

DesignCompanion clinical metabolomics analysis
ModelHuman participants; see population
Sample60 participants represented by serum samples
InterventionMetabolomic analysis before/after berberine or placebo
DurationTreatment period not specified in accessible abstract
EndpointsFasting and postload glucose; HbA1c and insulin sensitivity; Lipid profile and tolerability

What the study showed, in plain terms

Serum profiling identified changes in free fatty acids after berberine exposure. This is a mechanistic metabolomics report, not a new demonstration of improved clinical outcomes.

Key findings

  • Serum profiling identified changes in free fatty acids after berberine exposure. This is a mechanistic metabolomics report, not a new demonstration of improved clinical outcomes.

What this study can and cannot tell us

Potential overlap with earlier diabetes cohorts; do not add its participants as independent without checking the parent trial.

Source detail: indexed abstract and bibliographic record; unavailable methods or disclosures are identified rather than assumed.

Related papers in the corpus

Tier 2
The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial
Mansour A et al. · European journal of nutrition · 2025
Tier 2
Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes
Nikseresht M et al. · Physiological reports · 2024
Tier 2
Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial
Panigrahi A et al. · BMC endocrine disorders · 2023
Tier 2
Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial
Rondanelli M et al. · European review for medical and pharmacological sciences · 2023
Tier 2
Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection
Ruiz-Herrera VV et al. · International journal of STD & AIDS · 2023

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology